OOIR: Observatory of International Research

Papers

(The TQCC of Platelets is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Prostacyclin analogues decrease platelet aggregation but have no effect on thrombin generation, fibrin clot structure, and fibrinolysis in pulmonary arterial hypertension: PAPAYA coagulation	64
Contributing role of mitochondrial energy metabolism on platelet adhesion, activation and thrombus formation under blood flow conditions	36
Predictive performance of different bleeding risk scores in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention	31
Enhanced platelet sensitization is accompanied by increased expression of the transporter MRP4 and elevated plasma S1P levels in mild COVID-19 convalescents	30
Platelet-derived microparticles stimulated by anti-β ₂ GPI/β ₂ GPI complexes induce pyroptosis of endothelial cells in antiphospho	28
Development of an automated chemiluminescence enzyme immunoassay for the measurement of soluble C-type lectin-like receptor 2 (sCLEC-2) and molecular forms of sCLEC-2 measured in patient plasma	27
Trends among platelet function, arterial calcium, and vascular function measures	26
The role of miRNAs in regulation of platelet activity and related diseases - a bioinformatic analysis	25
How can we use proteomics to learn more about platelets?	22
Apoptosis is one cause of thrombocytopenia in patients with high-altitude polycythemia	21
Chronic immune thrombocytopenia in a child with X-linked agammaglobulinemia-an uncommon phenotype	20
The natural anticoagulant protein S; hemostatic functions and deficiency	18
Increased circulating platelet-derived extracellular vesicles in severe COVID-19 disease	17
Sex-specific relationship between blood selenium levels and platelet count in a large cohort representative of the United States population	17
Dual antiplatelet therapy is associated with high α-tubulin acetylation in circulating platelets from coronary artery disease patients	16
Pro106Leu MPL mutation is associated with thrombocytosis and a low risk of thrombosis, splenomegaly and marrow fibrosis	16
Platelets and open access – a new era dawns	16
Clinical features and treatment effect of HIV-associated immune thrombocytopenia—single center Ten-Years data summary	16
Association between megakaryocyte abnormalities on bone marrow smear and response to thrombopoietin receptor agonists in adult patients with primary immune thrombocytopenia	15
Extracellular thiol isomerase ERp5 regulates integrin αIIbβ3 activation by inhibition of fibrinogen binding	15
Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study	14
Variation in activation marker expression within the platelet population – a new parameter for evaluation of platelet flow cytometry data	13
Potential mechanisms involved on how systemic IgG antibodies specific to vascular endothelial growth factor (VEGF) and induced by active immunotherapy decrease platelet derived free-VEGF	13
Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure	13
Effects of exercise on platelet reactivity after myocardial infarction: a randomized clinical trial	13

European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia	12
Platelet response to aspirin in UK and Irish pregnancy cohorts: a genome-wide approach	12
Phosphorylation of (Ser 291) in the linker insert of Syk negatively regulates ITAM signaling in platelets	12
Apolipoprotein A-I, elevated in trauma patients, inhibits platelet activation and decreases clot strength	11
Recent advances in microfluidic technology of arterial thrombosis investigations	11
Circulating microRNAs as biomarkers and mediators of platelet activation	11
Inflammation modifies the platelet reactivity among thrombocytopenia patients undergoing percutaneous coronary intervention	11
Potential and limitations of PKA/ PKG inhibitors for platelet studies	11
Developmental differences of in vitro cultured murine bone marrow- and fetal liver-derived megakaryocytes	11
Identification of UDP-Glucuronosyltransferase mRNA in human platelets: differential levels in smokers and non-smokers	11
Tirofiban potentiates agonist-induced platelet activation and degranulation, despite effectively inhibiting aggregation	11
Impact of thrombocytopenia-associated c.-118C>T and c.-140C>G ANKRD26 5’UTR variants in three-generational pedigree	11
miR-28-5p targeted Rap1b attenuates splenic inflammation infiltration in immune thrombocytopenia	10
A splice mutation in RASGRP2 gene in the patient with recurrent epistaxis and nasal vascular malformation	10
Association of thromboxane generation with the bleeding events in aspirin users	10
Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology	10
Deep learning, 3D ultrastructural analysis reveals quantitative differences in platelet and organelle packing in COVID-19/SARSCoV2 patient-derived platelets	10
Evolution of platelet activation parameters during septic shock in intensive care unit	10
The effect of testosterone on platelet activation and inflammation in transgender men	10
Higher body mass index raises immature platelet count: potential contribution to obesity-related thrombosis	10
Cardiometabolic risk factor burden associates with an immature platelet profile	10
Role of platelet count in a murine stasis model of deep vein thrombosis	10
Neurosurgical bleeding in platelet storage pool disorder: a case report	10
In memory of Dr. Susan S. Smyth, MD/Ph.D.	10
Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective	9
Factors influencing platelet isolation: a prospective multicenter study from Western China	9
Application of the Cellular Thermal Shift Assay (CETSA) to validate drug target engagement in platelets	9
Efficacy and safety of two rituximab biosimilars for treating immune thrombocytopenia: a reference-product matched study	9
Q94 is not a selective modulator of proteinase-activated receptor 1 (PAR1) in platelets	9
The safety and efficacy of indobufen or aspirin combined with clopidogrel in patients with acute myocardial infarction after percutaneous coronary intervention	9
What can we learn from senescent platelets, their transcriptomes and proteomes?	9
Congenital thrombocytopenia associated with a heterozygous variant in the MEIS1 gene encoding a transcription factor essential for megakaryopoiesis	9
Age and outcomes following personalized antiplatelet therapy in chronic coronary syndrome patients: a post hoc analysis of the randomized PATH-PCI trial	9
Early recognition of sepsis-induced coagulopathy using the C2PAC index: a ratio of soluble type C lectin-like receptor 2 (sCLEC-2) level and platelet count	9
Evaluation of human platelet granules by structured illumination laser fluorescence microscopy	9
In vitro evaluation of platelet extracellular vesicles (PEVs) for corneal endothelial regeneration	9
Multiple myeloma and its treatment contribute to increased platelet reactivity	9
Platelet-derived respiratory-competent mitochondria transfer to mesenchymal stem cells to promote wound healing via metabolic reprogramming	8
New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans	8
Association between endometriosis, infertility and autoimmune antiplatelet glycoprotein VI antibodies in two patients	8
Thrombocytopathy vs Platelet hyper-reactivity in COVID-19: diverse pathologies, disease outcomes and therapeutic implications	8
Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies	8
Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors	8
Platelet counts in HFE p.C282Y/p.C282Y and wt/wt post-screening clinical evaluation participants	8
Comparison of in-hospital net clinical outcomes of ticagrelor and clopidogrel in acute coronary syndrome patients stratified by CRUSADE score: findings from the CCC-ACS registry	8
Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia	8
Evaluating stored platelet shape change using imaging flow cytometry	8
Alantolactone induces platelet apoptosis by activating the Akt pathway	8
Appraising non-linear association between pre-diagnostic platelet counts and cancer survival outcomes: observational and genetic analysis	8
Deficiency of BLOS1 moderately impairs the biogenesis of platelet dense granules	8